Biodefense

Since the mailings of anthrax laden letters in 2001 killed five people and exposed hundreds more, the biodefense industry has grown into a significant and established market. As terrorists refine their tactics, the looming threat of biological weapons and naturally emerging pandemic threats continue to expand. From 2001-2009, the U.S. spent approximately $50 billion on defense against biological and pandemic threats. Other international bodies such as the EU, China, India and Israel are also increasing their investments in biodefense.

Top pathogenic bacterial threats in the biodefense market include Bacillus anthracis (anthrax) and Yersina pestis (bubonic plague). To address these threats, NanoLogix has developed simple and cost-effective testing for both of these pathogens that use its patented live cell rapid detection technology.

Conventional Petri cultures detect anthrax in 24 hours. With NanoLogix technology, EMS first responders and military personnel can receive live-cell anthrax results 75 percent faster, or, in as little as 6 hours. When it comes to bubonic plague, conventional Petri tests can take at least 48 hours to achieve accurate results. NanoLogix technology cuts that time in half, returning results in 24 hours.

For a detailed report on how the NanoLogix BNP™ technology performs with anthrax and bubonic plague, please read the study by Rogers, J.V., and Y.W. Choi, published in the Letters in Applied Microbiology, titled, Decreased time for detection and quantification of virulent Bacillus anthracis and Yersinia pestis using a BioNanoPore (BNP™) membrane technology.(PDF)